Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.|
|Citation:||The Journal of Molecular Diagnostics, 2022; 24(7):803-822|
|Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, Nur Hezrin Shahrin, Chloe Vignaud, Vanessa Obourn, Shalini Chaturvedi, Feng Yang, Jinghua Feng, Verity Saunders, Chung H. Kok, David Yeung, Rob M. King, Rosalie R. Kenyon, Ming Lin, Paul Wang, Hamish Scott, Timothy Hughes, Andreas W. Schreiber, and Susan Branford|
|Abstract:||Mutation detection is increasingly used for the management of hematological malignancies. Prior whole transcriptome and whole exome sequencing studies using total RNA and DNA identified diverse mutation types in cancer-related genes associated with treatment failure in patients with chronic myeloid leukemia. Variants included single-nucleotide variants and small insertions/deletions, plus fusion transcripts and partial or whole gene deletions. The hypothesis that all of these mutation types could be detected by a single cost-effective hybridization capture next-generation sequencing method using total RNA was assessed. A method was developed that targeted 130 genes relevant for myeloid and lymphoid leukemia. Retrospective samples with 121 precharacterized variants were tested using total RNA and/or DNA. Concordance of detection of precharacterized variants using RNA or DNA was 96%, whereas the enhanced sensitivity identified additional variants. Comparison between 24 matched DNA and RNA samples demonstrated 95.3% of 170 variants detectable using DNA were detected using RNA, including all but one variant predicted to activate nonsense-mediated decay. RNA identified an additional 10 variants, including fusion transcripts. Furthermore, the true effect of splice variants on RNA splicing was only evident using RNA. In conclusion, capture sequencing using total RNA alone is suitable for detecting a range of variants relevant in chronic myeloid leukemia and may be more broadly applied to other hematological malignancies where diverse variant types define risk groups.|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
High-Throughput Nucleotide Sequencing
|Rights:||Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.